LABGENOMICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,220 KRW | -1.11% |
|
-9.20% | -42.41% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 1479.96 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -42.41% | 119M | - | ||
| -15.80% | 8.55B | B+ | ||
| +64.74% | 4.23B | C+ | ||
| +4.92% | 2.68B | B- | ||
| -2.80% | 2.61B | - | ||
| -54.53% | 1.82B | B- | ||
| -19.59% | 1.66B | C- | ||
| -21.51% | 1.42B | A- | ||
| +15.98% | 1.19B | B+ | ||
| -48.13% | 1.05B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- A084650 Stock
- Ratings LabGenomics Co., Ltd.
